Login
Navigate Fool.com
Will NBIX beat
the market?
Community Rating: 2 Stars: Unattractive

13.78 0.00 (0.00%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $13.89
Previous Close $13.78
Daily Range $13.04 - $14.20
52-Week Range $8.57 - $20.29
Market Cap $1.0B
P/E Ratio -19.97
Dividend (Yield) $0.00 (0.0%)
Volume 199,451
Average Daily Volume 991,339
Current FY EPS -$0.87

How do you think NBIX
will perform against the market?

Top NBIX Bull/Bear Pitches

 

bhessel (< 20)
Submitted December 27, 2007

22 May 07 As with Élan—one of our other biotechs—Neurocrine Biosciences (NBIX) have had their ups and downs. The stock was at an all-time high $70 14 months ago when the FDA somewhat surprizingly tur … More

5 Replies Reply Report this Post
 

TMFUltraLong (< 20)
Submitted June 22, 2010

Neurocrine Biosciences, how you are still an operational entity is beyond my comprehension. NBIX has signed two deals over the last two days, with Abbott and a smaller deal with Boehringer to supply t … More

1 Replies Reply Report this Post

News & Commentary Rss Feed

Can You Still Ride This Month's 3 Biggest Winners To Greater Gains?

Biotech dominates in January as Intercept, Cell Therapeutics, and Neurocrine all surge after good drug-trial news.

Neurocrine Biosciences (NBIX) Shares Cross Below 200 DMA

Piper Jaffray’s Seven Biotech Stocks to Buy With Huge Potential Upside

3 Stocks to Get on Your Watchlist

A big-box retail giant, an up-and-coming developer of a tardive dyskinesia treatment, and a short-sale candidate.

This Week in Biotech: Putting On a Clinic

In part one of This Week in Biotech we're looking at four encouraging clinical trials, including a company that gained 545%, as well as an announced collaboration and a buyout.

3 Humongous Health-Care Stocks This Week

Intercept Pharmaceuticals, Neurocrine Biosciences, and Epizyme achieve stunning gains in a great week for health-care investors.

Neurocrine Biosciences Inc. Nearly Doubles (but Not Really)

Neurocrine Biosciences isn't up nearly as much as it appears.

Why Neurocrine Biosciences, Epizyme, and Plug Power Are Today's 3 Best Stocks

The S&P 500 delivers its first gain of the year while Neurocrine Biosciences, Epizyme, and Plug Power all rocket higher by at least 39%!

Mid-Afternoon Market Update: Markets Post Large Rally as Textron Falls on Citron Report

Why Epizyme, Neurocrine Biosciences, and Peregrine Soared

These 3 biotechs could beat the broader market this year.

See More NBIX News...

Sector

Healthcare

Industry

Drugs

Neurocrine Biosciences, Inc. (NBIX) Description

Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis. Website: http://www.neurocrine.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks